학술논문

Combined Targeted Therapies for First-line Treatment of Metastatic Triple Negative Breast Cancer—A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib
Document Type
Article
Source
In Clinical Breast Cancer April 2019 19(2):e283-e296
Subject
Language
ISSN
1526-8209